icon

Shares of Ampio Pharmaceuticals (AMPE) have rebounded by roughly three bucks over the past few weeks as many major catalysts are set to materialize later this year and eary next. As the latter stages of development of the company's 'respositioned' pipeline are being transitioned for the commercial p...

Read more

Capstone Turbine (CPST) has become a perpetual member of the 'Weekly Stock Watch' list since rising to over the two dollar mark earlier this year and then dropping back down to a buck on heavy short interest as the broad market declined.

That's not to say, however, that positive developments have co...

Read more

Cel-Sci Corp. announced last week that it had entered a sales, marketing and distribution agreement for Multikine in Venezuela and Argentina. Multikine is the company's Phase III immunotherapeutic treatment for head and neck cancer and the deal was signed with IDC-GP Pharm LLC, a joint venture betwe...

Read more

Some stocks and stories to watch this week:

CPST: Capstone Turbine (CPST) has become a perpetual part of the 'Weekly Stock Watch' list since dropping to the dollar mark on heavy short interest and the broad market downtick, but some news releases within the past week give reinvigorated life to the co...

Read more

Shortly after announcing that the new Smart InSole had reached market, BioElectronics follow-up with news that the company will now target the C-Section market. A new clinical trial will be headed by "Jose Carvalho, MD, PhD, FANZCA, FRCPC, Professor and Director of Anesthesia and Obstetrics and Gyne...

Read more

It's been a roller-coaster year for Cytsosorbents thus far, starting with a surprise European approval for the company's cytokine filter, CytoSorb, which sent shares tripling into the forty cent range. That quick rise was followed by a price slide that had some investors fearful that there might be ...

Read more

On Friday evening, Dendreon (DNDN) announced that the FDA had approved its third Provenge manufacturing facility (in Atlanta), news that would ordinarily be well-recepted by investors and add momentum to a company whose 'Golden Age' had been materializing before our very eyes.

However, a monumental s...

Read more

Some companies in the biotech and pharmaceutical sectors making news this week:

APRI: Shortly after announcing that the FDA had granted clearance to Apricus Bio's wholly-owned subsidiary, NexMed USA, to market the anti-fungal cream Tolnaftate-D, marking the first such clearance for the NexAct drug d...

Read more

With the first stages of the BluScience product line roll-out having taken place on the GNC website - with a move into GNC stores set to commence in September - ChromaDex Corp. kicked it up another notch by partnering with two major public relations and media awareness players in the health and well...

Read more

Good news for investors of BioDelivery Sciences.

A Monday morning press release announced that the company's treatment for breakthrough pain in cancer patients, Onsolis, will be available for sale on the Canadian market at some point during the current quarter.

Onsolis is already on the market in the ...

Read more

Generex (GNBT) subsidiary Antigen Express provided an update on its cancer immunotherapy AE37 last week, but the news - which was the announcement of positive interim results - failed to move the GNBT share price as a positive Oral-lyn update did just weeks prior.

In fact, amid the recent market tur...

Read more

With the BIEL share price slipping back towards a penny after recently defying the falling market and running towards two, the company issued a press release last week introducing a new foot care product, the Smart Insole.

The product looks to have some major potential in the multi-billion dollar foo...

Read more

As Ampio Pharmaceuticals (AMPE) uses repositioned products to position itself for major growth, the management team is also being fortified to carry out the short and long term missions of the company.

Already boasting a team with decades of experience and expertise, the company announced on Monday t...

Read more

Some stocks and stories worth watching this week.

AMPE: Ampio has traded with some volatility over the past few weeks, but hasn't been hit as hard as other developmental companies during the latest round of the stock market storm. With quite a few catalysts due before the end of 2011- including the ...

Read more

A few stocks making headlines these days and my be worth investor attention:

MNKD: Mannkind has been hammered all year long after receiving another denial from the FDA in January for the approval of the company's inhaled insulin product, Afrezza. Solid back-up news was slow to materialize and shares ...

Read more

With multiple near term catalysts coming due, Ampio Pharmaceuticals may be on the verge of making a big splash in the health care sector.

Ampio brings a unique approach to the plate in the health care sector, as its strategy of repositioning already-approved drugs to treat new indications reduces th...

Read more

The Market: With the market bouncing all over the place over the past couple of weeks, it's paramount to keep an eye on the public sentiment, as stocks will continue to trade along with that sentiment and not necessarily on fundamentals or material events. It's also an opportune time for shorts to t...

Read more

In continuing the ongoing series of companies and stocks that might look a whole lot more attractive during the current market meltdown, here's a few more not to ignore...

It's hard to write about this subject without bringing Dendreon (DNDN) into the picture. After all, many media outlets and big in...

Read more

Updating this story posted on Monday, the ChromaDex BluScience line is available on the GNC.com website under 'BluScience' and 'New Products'. Take a look by clicking HERE.

With August now upon us, it's game time for ChromaDex Corp.

As previously reported, August is the expected timeframe for the comm...

Read more

Back in late 2008, and early 2009, the stock market was crashing - and crashing hard.

It was the height of the global recession - often called a depression - and investors were bailing left and right from the market and citizens of the world panicked that their 401Ks and IRAs would never recover.

But ...

Read more

Amid The Chaos, There's BIEL

Posted by Posted by VFC on Aug 08, 2011

Last month VFC's Stock House took a look at 'The Good, The Bad And The Ugly' aspects of Biel Corp, a company long waiting on positive developments from the FDA to re-ignite a run similar to the one a couple of years ago that saw shares of BIEL trade from sub-penny to twelve cents.

Although there's no...

Read more

Dendreon (DNDN), a company whose key catalysts have been turning out for the best for a couple of years running now took a drastic hit in share price after an earnings report on Wednesday evening revealed that Provenge sales were not quite meeting analyst, investor or even the company's expectations...

Read more

In another demonstration of just how far SiriusXM radio has come since the woes of the economic crisis, when SIRI slipped to as low as a nickel, the company banked another quarter of record earnings and added an additional 450,000-plus subscriptions.

That puts the running total at just about 21 milli...

Read more

As a follow-up to my recent "Falling Health Care Stocks" post, here's a few more to take a look at. Opportunities may be a-plenty if Tuesday's market dive continues.

TTNP: Titan continues to trade for under the two dollar price mark, even after releasing historic news last month with confirmation tha...

Read more

It's been over a month since the dramatic drop in the Generex share price, and aside from a temporary boost provided on the heels of a positive Oral-lyn update, there hasn't been much movement in the GNBT share price, which looks stuck in the teens.

Shareholders did vote through a reverse split earli...

Read more

While shares of CYTR have dipped into the low forty cents range following the announcement of a direct offering last week, the new week opened up with another round of encouraging news regarding INNO-206, an experimental doxorubicin conjugate that targets cancerous tumors which was recently granted ...

Read more

Some health care stocks that have slipped from recent highs and might be worth keeping an eye on:


ONTY: Can we really call Oncothyreon a "falling stock" while it's still trading as just about a double this year?

Looks like it.

This Year's ONTY run had the stock flying straight to the ten dollar mark as...

Read more